Home›Diabetes & Endocrinology› Biochemical remission of Cushing's syndrome reduces hepatic steatosis and fibrosis indices in adult patients
Biochemical remission of Cushing's syndrome reduces hepatic steatosis and fibrosis indices in adult patientsCushing’s Syndrome Often Leads to Fatty Liver Disease
Frontiers in MedicinePublished April 24, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that biochemical remission reduces hepatic steatosis indices in Cushing's syndrome, though MASLD prevalence remains high.
This retrospective cohort study examined 126 adult patients with endogenous Cushing's syndrome (CS) to assess the impact of biochemical remission on metabolic dysfunction–associated steatotic liver disease (MASLD). The primary outcome measured the prevalence of MASLD and changes in hepatic steatosis and fibrosis-related indices following remission, with a follow-up period of six months after biochemical remission. The comparator was the active disease phase.
At baseline, MASLD was present in 62.7% of patients. There was no significant difference in MASLD prevalence between patients with adrenal and pituitary CS. Following remission, hepatic steatosis indices (HSI) decreased in both adrenal and pituitary CS groups, with a p-value less than 0.01 for both. Overall FIB-4 values did not change, but significant reduction occurred in patients with elevated baseline fibrosis risk (FIB-4 ≥1.3), with a p-value of 0.010.
Multivariate analysis identified higher body mass index, longer duration of symptoms before diagnosis, and adrenal CS as independent predictors of MASLD, with adjusted odds ratios of 1.30, 1.06, and 2.90, respectively. Increasing age was inversely associated with MASLD. Biochemical measures of cortisol excess were not independently related to MASLD. Safety data, adverse events, and tolerability were not reported. The study authors note that data on prevalence, determinants, and reversibility after remission remain limited and inconsistent.
These findings support routine hepatic assessment in CS, particularly for patients with prolonged disease duration and increased metabolic risk. However, the retrospective nature and inconsistent data on reversibility suggest these results should be interpreted with caution.
Fatty Liver Disease Common in Cushing’s Syndrome
A new report looks at how this hormone affects the liver. It found that more than 60% of patients have fatty liver disease. This is a condition where fat builds up inside the liver cells. It is not a rare problem for these patients.
Doctors used to focus on the hormone levels alone. They did not always check the liver closely. This new research changes how they look at the disease. It shows the liver is a major target for damage.
Liver Fat Improves After Treatment
Think of cortisol like a key that turns on fat storage. When it stays on, fat builds up in the liver. The study checked patients before and after their treatment. They found that the fat went down after the hormone levels normalized.
This improvement happened in both adrenal and pituitary cases. It means the liver can heal if the cause is fixed. But there is a catch. The scarring in the liver did not always go away.
Why Some Risks Stay Higher
Patients with high baseline fibrosis risk saw a drop. Fibrosis is the medical word for scarring in the organ. If the risk was low to start, it stayed low. But if it was high, it only went down a bit.
This doesn't mean this treatment is available yet.
The study looked at 126 adults with Cushing’s syndrome. They checked their livers using ultrasound and blood tests. The team measured fat and scarring at two different times. They compared the results to find patterns in the data.
Experts say this helps doctors know what to watch for. It changes how they check patients during their care. It is important to manage weight and blood sugar levels. These factors drive the disease more than the hormone itself.
Higher body weight and longer symptom duration were key signs. Adrenal causes of the syndrome also raised the risk. Age was linked to a lower risk in this group. This suggests younger patients need more careful monitoring.
The study had some limits that matter to you. It was not a large trial for everyone. It was also a look back at past records. This means we need more research to confirm the results.
More research is needed to see long-term effects. Doctors will keep watching how patients heal over time. Approval for new treatments takes time and careful testing. You should talk to your doctor about liver health.
More on Metabolic Dysfunction-Associated Steatotic Liver Disease
BackgroundMetabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a systemic manifestation of endocrine disorders. Cushing’s syndrome (CS), characterized by chronic endogenous hypercortisolism, is associated with profound metabolic disturbances that may predispose to MASLD; however, data on its prevalence, determinants, and reversibility after remission remain limited and inconsistent.ObjectiveTo evaluate the prevalence of MASLD in patients with CS, assess changes in hepatic steatosis and fibrosis-related indices following biochemical remission, and identify independent clinical, metabolic, and etiological predictors of MASLD.MethodsIn this retrospective study, 126 adult patients with endogenous CS diagnosed between 2014 and 2025 were included. MASLD was defined according to contemporary consensus criteria. Imaging-based hepatic steatosis was evaluated by abdominal ultrasonography. Hepatic steatosis and fibrosis risk were assessed using the hepatic steatosis index (HSI) and Fibrosis-4 index (FIB-4), respectively, during the active disease phase and six months after biochemical remission. Comparisons were performed between adrenal and pituitary CS. Logistic regression analyses were used to identify factors independently associated with MASLD.ResultsMASLD was present in 62.7% of patients with CS. At baseline, MASLD prevalence did not differ significantly between adrenal and pituitary CS. HSI decreased from the active phase to six months after remission in both adrenal and pituitary CS (p < 0.01 for both), indicating partial reversibility of hepatosteatosis following cortisol normalization. Overall, FIB-4 values did not change; however, patients with elevated baseline fibrosis risk (FIB-4 ≥1.3) demonstrated a significant reduction after remission (p = 0.010). In multivariate analysis, higher body mass index (adjusted OR 1.30), longer duration of symptoms before diagnosis (adjusted OR 1.06), and adrenal CS (adjusted OR 2.90) were independently associated with MASLD, whereas increasing age was inversely associated. Biochemical measures of cortisol excess were not independently related to MASLD.ConclusionsMASLD is highly prevalent in CS and is primarily driven by metabolic burden, disease chronicity, and etiology rather than by biochemical severity of hypercortisolism. Hepatic steatosis shows partial improvement after remission, whereas the risk of fibrosis declines primarily among patients with elevated baseline risk. These findings support routine hepatic assessment in CS, particularly those with prolonged disease duration and increased metabolic risk.
